Chin H. Lee

873 total citations · 1 hit paper
6 papers, 687 citations indexed

About

Chin H. Lee is a scholar working on Rheumatology, Social Psychology and Hematology. According to data from OpenAlex, Chin H. Lee has authored 6 papers receiving a total of 687 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Rheumatology, 2 papers in Social Psychology and 2 papers in Hematology. Recurrent topics in Chin H. Lee's work include Spondyloarthritis Studies and Treatments (2 papers), Systemic Lupus Erythematosus Research (2 papers) and Psoriasis: Treatment and Pathogenesis (2 papers). Chin H. Lee is often cited by papers focused on Spondyloarthritis Studies and Treatments (2 papers), Systemic Lupus Erythematosus Research (2 papers) and Psoriasis: Treatment and Pathogenesis (2 papers). Chin H. Lee collaborates with scholars based in United States, Canada and Japan. Chin H. Lee's co-authors include Catherine L Shuler, Philip J. Mease, Chen‐Yen Lin, Dafna Gladman, Désirée van der Heijde, Daniel Braun, Raquel Cuchacovich, Christopher T. Ritchlin, Masato Okada and Scott D. Beattie and has published in prestigious journals such as Annals of the Rheumatic Diseases, Lara D. Veeken and Computers & Industrial Engineering.

In The Last Decade

Chin H. Lee

5 papers receiving 675 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

2016 431 citations Philip J. Mease, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →

Peers

Countries citing papers authored by Chin H. Lee

Since Specialization

Citations

This map shows the geographic impact of Chin H. Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chin H. Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chin H. Lee more than expected).

Fields of papers citing papers by Chin H. Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chin H. Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chin H. Lee. The network helps show where Chin H. Lee may publish in the future.

Co-authorship network of co-authors of Chin H. Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Chin H. Lee. A scholar is included among the top collaborators of Chin H. Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chin H. Lee. Chin H. Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

#	Work	Indexed citations
1	Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1) 2018 ·Lara D. Veeken ·Alice B. Gottlieb, Vibeke Strand, Mitsumasa Kishimoto, Philip J. Mease, Diamant Thaçi, Julie Birt, Chin H. Lee, Catherine L Shuler, Chen‐Yen Lin, Dafna D. Gladman	27
2	Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1 breakdown → 2016 ·Annals of the Rheumatic Diseases ·Philip J. Mease, Désirée van der Heijde, Christopher T. Ritchlin, Masato Okada, Raquel Cuchacovich, Catherine L Shuler, Chen‐Yen Lin, Daniel Braun, Chin H. Lee, Dafna Gladman	431
3	Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate 2014 ·Annals of the Rheumatic Diseases ·Edward Keystone, Peter C. Taylor, Edit Drescher, Douglas Schlichting, Scott D. Beattie, Pierre‐Yves Berclaz, Chin H. Lee, (unknown), Monica Luchi, Terence Rooney, William L. Macias, Mark C. Genovese	225
4	Human-computer interfaces: Modelling and evaluation 1991 ·Computers & Industrial Engineering ·Chin H. Lee, (unknown)	2
5	Ergonomic issues in quality control 1989 ·Computers & Industrial Engineering ·Ahmad Elshennawy, Chin H. Lee, (unknown)	1
6	Human-computer interaction in manufacturing 1987 ·Computers & Industrial Engineering ·Ahmad Elshennawy, Chin H. Lee	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact